ArticleJournal of virology2000
Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- Article
- Flaviviruses in AntiTumor Therapy.Viruses · 2023Review
- Reinventing positive-strand RNA virus reverse genetics.Advances in virus research · 2022Article
- Article
- Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer.Vaccines · 2021Review
- Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.Viruses · 2020Review
- Review
- Self-Amplifying RNA Viruses as RNA Vaccines.International journal of molecular sciences · 2020Review
- Repurposing the yellow fever vaccine for intratumoral immunotherapy.EMBO molecular medicine · 2020Article
- Self-Replicating RNA Viruses for RNA Therapeutics.Molecules (Basel, Switzerland) · 2018Review
- The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.Journal of virology · 2016Article
- Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.The Journal of general virology · 2015Article
- CD8+ T cells complement antibodies in protecting against yellow fever virus.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Improved genetic stability of recombinant yellow fever 17D virus expressing a lentiviral Gag gene fragment.Virology · 2014Article
- Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation.Science (New York, N.Y.) · 2014Article
- The yellow fever 17D virus as a platform for new live attenuated vaccines.Human vaccines & immunotherapeutics · 2014Review
- Article
- Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.Virology journal · 2011Article
- Article
- Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.Journal of biomedicine & biotechnology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We have genetically engineered an attenuated yellow fever (YF) virus to carry and express foreign antigenic sequences and evaluated the potential of this type of recombinant virus to serve as a safe and effective tumor vaccine. Live-attenuated YF vaccine is one of the most effective viral vaccines available today. Important advantages include its ability to induce long-lasting immunity, its safety, its affordability, and its documented efficacy. In this study, recombinant live-attenuated (strain 17D) YF viruses were constructed to express a cytotoxic T-lymphocyte epitope derived from chicken ovalbumin (SIINFEKL). These recombinant viruses replicated comparably to the 17D vaccine strain in cell culture and stably expressed the ovalbumin antigen, and infected cells presented the antigen in the context of major histocompatibility complex class I. Inoculation of mice with recombinant YF virus elicited SIINFEKL-specific CD8(+) lymphocytes and induced protective immunity against challenge with lethal doses of malignant melanoma cells expressing ovalbumin. Furthermore, active immunotherapy with recombinant YF viruses induced regression of established solid tumors and pulmonary metastases. Thus, recombinant YF viruses are attractive viral vaccine vector candidates for the development of therapeutic anticancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.